NCT00509795

Brief Summary

This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,217

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Aug 2007

Typical duration for phase_3

Geographic Reach
2 countries

188 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 31, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 1, 2007

Completed
Same day until next milestone

Study Start

First participant enrolled

August 1, 2007

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2010

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
10 months until next milestone

Results Posted

Study results publicly available

April 16, 2012

Completed
Last Updated

December 28, 2012

Status Verified

December 1, 2012

Enrollment Period

3.1 years

First QC Date

July 31, 2007

Results QC Date

December 16, 2011

Last Update Submit

December 20, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)

    Defined "maintenance of vision" as patients who lost fewer than 15 letters in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score compared to baseline.

    Baseline and at week 52

Secondary Outcomes (4)

  • Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF

    Baseline and at week 52

  • Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF.

    Baseline and at week 52

  • Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF

    Baseline and at Week 52

  • Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF)

    Baseline and at week 52

Study Arms (4)

ranibizumab 0.5mg Q4

ACTIVE COMPARATOR
Biological: ranibizumab

aflibercept injection 2.0mg Q4

EXPERIMENTAL
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)

aflibercept injection 0.5mg Q4

EXPERIMENTAL
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)

aflibercept injection 2.0mg Q8

EXPERIMENTAL
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)

Interventions

ranibizumabBIOLOGICAL

Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

Also known as: Lucentis
ranibizumab 0.5mg Q4

Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

Also known as: VEGF Trap-Eye, BAY86-5321
aflibercept injection 2.0mg Q4

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signed Informed Consent.
  • Men and women ≥ 50 years of age.
  • Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye.
  • Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) of: letter score of 73 to 25 (20/40 to 20/320) in the study eye at 4 meters.
  • Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
  • Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member. See Appendix J.4) understand and willing to sign the informed consent form.
  • Key

You may not qualify if:

  • Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD except dietary supplements or vitamins.
  • Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye, except dietary supplements or vitamins.
  • Any prior treatment with anti-VEGF agents in the study eye.
  • Total lesion size \> 12 disc areas (30.5 mm\^2, including blood, scars and neovascularization) as assessed by FA in the study eye.
  • Subretinal hemorrhage that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye. (If the blood is under the fovea, then the fovea must be surrounded 270 degrees by visible CNV.)
  • Scar or fibrosis, making up \> 50% of total lesion in the study eye.
  • Scar, fibrosis, or atrophy involving the center of the fovea.
  • Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
  • History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.
  • Presence of other causes of CNV in the study eye.
  • History or clinical evidence of diabetic retinopathy, diabetic macular edema or any other vascular disease affecting the retina,other than AMD, in either eye.
  • Prior vitrectomy in the study eye.
  • History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
  • Any history of macular hole of stage 2 and above in the study eye.
  • Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of day 1, as long as its unlikely to interfere with the injection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (188)

Unknown Facility

Birmingham, Alabama, 35205, United States

Location

Unknown Facility

Birmingham, Alabama, 35223, United States

Location

Unknown Facility

Phoenix, Arizona, 85014, United States

Location

Unknown Facility

Phoenix, Arizona, 85020, United States

Location

Unknown Facility

Tucson, Arizona, 85704, United States

Location

Unknown Facility

Tucson, Arizona, 85710, United States

Location

Unknown Facility

Beverly Hills, California, 90211, United States

Location

Unknown Facility

Campbell, California, 95008, United States

Location

Unknown Facility

Fullerton, California, 92835, United States

Location

Unknown Facility

Glendale, California, 91203, United States

Location

Unknown Facility

Irvine, California, 92697, United States

Location

Unknown Facility

La Jolla, California, 92037, United States

Location

Unknown Facility

Loma Linda, California, 92354, United States

Location

Unknown Facility

Los Angeles, California, 90033, United States

Location

Unknown Facility

Los Angeles, California, 90048, United States

Location

Unknown Facility

Menlo Park, California, 94025, United States

Location

Unknown Facility

Mountain View, California, 94040, United States

Location

Unknown Facility

Oakland, California, 94609, United States

Location

Unknown Facility

Palm Springs, California, 92262, United States

Location

Unknown Facility

Pasadena, California, 91105, United States

Location

Unknown Facility

Poway, California, 92064, United States

Location

Unknown Facility

Sacramento, California, 95819, United States

Location

Unknown Facility

San Diego, California, 92120, United States

Location

Unknown Facility

San Francisco, California, 94107, United States

Location

Unknown Facility

Santa Ana, California, 92705, United States

Location

Unknown Facility

Torrance, California, 90503, United States

Location

Unknown Facility

Ventura, California, 93003, United States

Location

Unknown Facility

Westlake Village, California, 91361, United States

Location

Unknown Facility

Yorba Linda, California, 92887, United States

Location

Unknown Facility

Aurora, Colorado, 80045, United States

Location

Unknown Facility

Denver, Colorado, 80205, United States

Location

Unknown Facility

Denver, Colorado, 80230, United States

Location

Unknown Facility

Bridgeport, Connecticut, 06606, United States

Location

Unknown Facility

Hamden, Connecticut, 06518, United States

Location

Unknown Facility

New Haven, Connecticut, 06510, United States

Location

Unknown Facility

New London, Connecticut, 06320, United States

Location

Unknown Facility

Altamonte Springs, Florida, 32701, United States

Location

Unknown Facility

Boynton Beach, Florida, 33426, United States

Location

Unknown Facility

Fort Lauderdale, Florida, 33351, United States

Location

Unknown Facility

Fort Myers, Florida, 33907, United States

Location

Unknown Facility

Fort Myers, Florida, 33912, United States

Location

Unknown Facility

Gainesville, Florida, 32610, United States

Location

Unknown Facility

Jacksonville, Florida, 32224, United States

Location

Unknown Facility

Miami, Florida, 33136, United States

Location

Unknown Facility

Miami, Florida, 33143, United States

Location

Unknown Facility

Mt. Dora, Florida, 32757, United States

Location

Unknown Facility

Orlando, Florida, 32803, United States

Location

Unknown Facility

Orlando, Florida, 32806, United States

Location

Unknown Facility

Oscala, Florida, 34472, United States

Location

Unknown Facility

Palm Beach Gardens, Florida, 33410, United States

Location

Unknown Facility

Pensacola, Florida, 32503, United States

Location

Unknown Facility

Sarasota, Florida, United States

Location

Unknown Facility

Stuart, Florida, 34994, United States

Location

Unknown Facility

Tampa, Florida, 33612, United States

Location

Unknown Facility

Winter Haven, Florida, 33880, United States

Location

Unknown Facility

Augusta, Georgia, 30909, United States

Location

Unknown Facility

Honolulu, Hawaii, 96813, United States

Location

Unknown Facility

‘Aiea, Hawaii, 96701, United States

Location

Unknown Facility

Oak Brook, Illinois, 60523, United States

Location

Unknown Facility

Fort Wayne, Indiana, 46804, United States

Location

Unknown Facility

Indianapolis, Indiana, 46202, United States

Location

Unknown Facility

Indianapolis, Indiana, 46260, United States

Location

Unknown Facility

Indianapolis, Indiana, 46280, United States

Location

Unknown Facility

New Albany, Indiana, 47150, United States

Location

Unknown Facility

Iowa City, Iowa, 52242-1091, United States

Location

Unknown Facility

Wichita, Kansas, 67214, United States

Location

Unknown Facility

Louisville, Kentucky, 40202, United States

Location

Unknown Facility

Louisville, Kentucky, 40207, United States

Location

Unknown Facility

Paducah, Kentucky, 42001, United States

Location

Unknown Facility

New Orleans, Louisiana, 70115, United States

Location

Unknown Facility

New Orleans, Louisiana, 70121, United States

Location

Unknown Facility

Shreveport, Louisiana, 71105, United States

Location

Unknown Facility

Bangor, Maine, 04401, United States

Location

Unknown Facility

Portland, Maine, 04102, United States

Location

Unknown Facility

Baltimore, Maryland, 21209, United States

Location

Unknown Facility

Baltimore, Maryland, 21287, United States

Location

Unknown Facility

Chevy Chase, Maryland, 20815, United States

Location

Unknown Facility

Hagerstown, Maryland, 21740, United States

Location

Unknown Facility

Towson, Maryland, 21204, United States

Location

Unknown Facility

Boston, Massachusetts, 02111, United States

Location

Unknown Facility

Boston, Massachusetts, 02114, United States

Location

Unknown Facility

Boston, Massachusetts, 02215, United States

Location

Unknown Facility

Boston, Massachusetts, United States

Location

Unknown Facility

Peabody, Massachusetts, 01960, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48105, United States

Location

Unknown Facility

Battle Creek, Michigan, 49015, United States

Location

Unknown Facility

Detroit, Michigan, 48202, United States

Location

Unknown Facility

Grand Rapids, Michigan, 49525, United States

Location

Unknown Facility

Jackson, Michigan, 49201, United States

Location

Unknown Facility

Royal Oak, Michigan, 48073, United States

Location

Unknown Facility

Southfield, Michigan, 48034, United States

Location

Unknown Facility

West Bloomfield, Michigan, 48322, United States

Location

Unknown Facility

Edina, Minnesota, 55435, United States

Location

Unknown Facility

Minneapolis, Minnesota, 55404, United States

Location

Unknown Facility

Rochester, Minnesota, 55905, United States

Location

Unknown Facility

Florissant, Missouri, 63031, United States

Location

Unknown Facility

Kansas City, Missouri, 64108, United States

Location

Unknown Facility

Kansas City, Missouri, 64111, United States

Location

Unknown Facility

Springfield, Missouri, 65804, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Missoula, Montana, 59801, United States

Location

Unknown Facility

Lincoln, Nebraska, 68506, United States

Location

Unknown Facility

Omaha, Nebraska, 68131, United States

Location

Unknown Facility

Las Vegas, Nevada, 89144, United States

Location

Unknown Facility

Lawrenceville, New Jersey, 08648, United States

Location

Unknown Facility

New Brunswick, New Jersey, 08901, United States

Location

Unknown Facility

Northfield, New Jersey, 08225, United States

Location

Unknown Facility

Teaneck, New Jersey, 07666, United States

Location

Unknown Facility

Toms River, New Jersey, 08753, United States

Location

Unknown Facility

Albuquerque, New Mexico, 87106, United States

Location

Unknown Facility

Albany, New York, 12206, United States

Location

Unknown Facility

Brooklyn, New York, 11223, United States

Location

Unknown Facility

Lynbrook, New York, 11563, United States

Location

Unknown Facility

New York, New York, 10003, United States

Location

Unknown Facility

New York, New York, 10021, United States

Location

Unknown Facility

New York, New York, 10032, United States

Location

Unknown Facility

Poughkeepsie, New York, 12601, United States

Location

Unknown Facility

Rochester, New York, 14620, United States

Location

Unknown Facility

Rochester, New York, 14642, United States

Location

Unknown Facility

Slingerlands, New York, 12159, United States

Location

Unknown Facility

Syracuse, New York, 13224, United States

Location

Unknown Facility

Asheville, North Carolina, 28803, United States

Location

Unknown Facility

Charlotte, North Carolina, 28210, United States

Location

Unknown Facility

Raleigh, North Carolina, 27607, United States

Location

Unknown Facility

Southern Pines, North Carolina, 28387, United States

Location

Unknown Facility

Winston-Salem, North Carolina, 27157, United States

Location

Unknown Facility

Cincinnati, Ohio, 45202, United States

Location

Unknown Facility

Cincinnati, Ohio, 45242, United States

Location

Unknown Facility

Columbus, Ohio, 43215, United States

Location

Unknown Facility

Toledo, Ohio, 43608, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73104, United States

Location

Unknown Facility

Ashland, Oregon, 97520, United States

Location

Unknown Facility

Portland, Oregon, 97210, United States

Location

Unknown Facility

Portland, Oregon, 97227, United States

Location

Unknown Facility

Salem, Oregon, 97302, United States

Location

Unknown Facility

Kingston, Pennsylvania, 18704, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19104, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19107, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19124, United States

Location

Unknown Facility

Pittsberg, Pennsylvania, 15231, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15212, United States

Location

Unknown Facility

Pittsburgh, Pennsylvania, 15213, United States

Location

Unknown Facility

West Mifflin, Pennsylvania, 15122, United States

Location

Unknown Facility

Wyomissing, Pennsylvania, 19610, United States

Location

Unknown Facility

Providence, Rhode Island, 02903-4928, United States

Location

Unknown Facility

Charleston, South Carolina, 29414, United States

Location

Unknown Facility

Columbia, South Carolina, 29223, United States

Location

Unknown Facility

Greenville, South Carolina, 29605, United States

Location

Unknown Facility

West Columbia, South Carolina, 29169, United States

Location

Unknown Facility

Rapid City, South Dakota, 57701, United States

Location

Unknown Facility

Memphis, Tennessee, 38119, United States

Location

Unknown Facility

Memphis, Tennessee, 38120, United States

Location

Unknown Facility

Nashville, Tennessee, 37203, United States

Location

Unknown Facility

Abilene, Texas, 79606, United States

Location

Unknown Facility

Austin, Texas, 78705, United States

Location

Unknown Facility

Corpus Cristi, Texas, 78413, United States

Location

Unknown Facility

Dallas, Texas, 75390, United States

Location

Unknown Facility

DeSoto, Texas, 75115, United States

Location

Unknown Facility

Fort Worth, Texas, 76102, United States

Location

Unknown Facility

Fort Worth, Texas, 76104, United States

Location

Unknown Facility

Galveston, Texas, 77555, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

McAllen, Texas, 78503, United States

Location

Unknown Facility

Odessa, Texas, 79761, United States

Location

Unknown Facility

San Antonio, Texas, 78240, United States

Location

Unknown Facility

Salt Lake City, Utah, 84107, United States

Location

Unknown Facility

Salt Lake City, Utah, 84132, United States

Location

Unknown Facility

Burlington, Vermont, 05401, United States

Location

Unknown Facility

Charlottesville, Virginia, 22908, United States

Location

Unknown Facility

Fairfax, Virginia, 22031, United States

Location

Unknown Facility

Richmond, Virginia, 23221, United States

Location

Unknown Facility

Seattle, Washington, 98104, United States

Location

Unknown Facility

Silverdale, Washington, 98383, United States

Location

Unknown Facility

Madison, Wisconsin, 53715, United States

Location

Unknown Facility

Madison, Wisconsin, 58705, United States

Location

Unknown Facility

Milwaukee, Wisconsin, 53226, United States

Location

Unknown Facility

Calgary, Alberta, T3E 7MB, Canada

Location

Unknown Facility

Vancouver, British Columbia, V5Z 3N9, Canada

Location

Unknown Facility

Victoria, British Columbia, V8V 1B3, Canada

Location

Unknown Facility

Halifax, Nova Scotia, B3H 2Y9, Canada

Location

Unknown Facility

London, Ontario, N6A 4G5, Canada

Location

Unknown Facility

Mississauga, Ontario, L4W 1W9, Canada

Location

Unknown Facility

Ottawa, Ontario, K1H8L6, Canada

Location

Unknown Facility

Toronto, Ontario, M4N3M5, Canada

Location

Unknown Facility

Toronto, Ontario, M5C 2T2, Canada

Location

Unknown Facility

Montreal, Quebec, H1T 2M4, Canada

Location

Unknown Facility

Montreal, Quebec, H3A 1A1, Canada

Location

Unknown Facility

Regina, Saskatchewan, S4T 1A5, Canada

Location

Related Publications (3)

  • Li E, Donati S, Lindsley KB, Krzystolik MG, Virgili G. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020 May 5;5(5):CD012208. doi: 10.1002/14651858.CD012208.pub2.

  • Moshfeghi DM, Thompson D, Saroj N. Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies. Br J Ophthalmol. 2020 Sep;104(9):1223-1227. doi: 10.1136/bjophthalmol-2019-315021. Epub 2019 Dec 11.

  • Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, Wang EC, Heier J, Kaiser P, Chong V, Korobelnik JF. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration. Ophthalmology. 2015 Mar;122(3):571-8. doi: 10.1016/j.ophtha.2014.09.024. Epub 2014 Nov 6.

MeSH Terms

Conditions

Macular Degeneration

Interventions

Ranibizumabaflibercept

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Results Point of Contact

Title
Clinical Trials Administrator
Organization
Regeneron Pharmaceuticals

Study Officials

  • Robert Vitti, MD

    Regeneron Pharmaceuticals

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 31, 2007

First Posted

August 1, 2007

Study Start

August 1, 2007

Primary Completion

September 1, 2010

Study Completion

July 1, 2011

Last Updated

December 28, 2012

Results First Posted

April 16, 2012

Record last verified: 2012-12

Locations